Abstract:Background: Humanization of mouse monoclonal antibodies (mAbs) is crucial for reducing their immunogenicity in humans. However, humanized mAbs often lose their binding affinities. Therefore, an in silico humanization method that can prevent the loss of the binding affinity of mAbs is needed. Methods: We developed an in silico V(D)J recombination platform in which we used V(D)J human germline gene sequences to design five humanized candidates of anti-tumor necrosis factor (TNF)-α mAbs (C1-C5) by using different human germline templates. The candidates were subjected to molecular dynamics simulation. In addition, the structural similarities of their complementarity-determining regions (CDRs) to those of original mouse mAbs were estimated to derive the weighted interatomic root mean squared deviation (wRMSDi) value. Subsequently, the correlation of the derived wRMSDi value with the half maximal effective concentration (EC50) and the binding affinity (KD) of the humanized anti-TNF-α candidates was examined. To confirm whether our in silico estimation method can be used for other humanized mAbs, we tested our method using the anti-epidermal growth factor receptor (EGFR) a4.6.1, anti-glypican-3 (GPC3) YP9.1 and anti-α4β1 integrin HP1/2L mAbs. Results: The R2 value for the correlation between the wRMSDi and log(EC50) of the recombinant Remicade and those of the humanized anti-TNF-α candidates was 0.901, and the R2 value for the correlation between wRMSDi and log(KD) was 0.9921. The results indicated that our in silico V(D)J recombination platform could predict the binding affinity of humanized candidates and successfully identify the high-affinity humanized anti-TNF-α antibody (Ab) C1 with a binding affinity similar to that of the parental chimeric mAb (5.13 × 10-10). For the anti-EGFR a4.6.1, anti-GPC3 YP9.1, and anti-α4β1 integrin HP1/2L mAbs, the wRMSDi and log(EC50) exhibited strong correlations (R2 = 0.9908, 0.9999, and 0.8907, respectively). Conclusions: Our in silico V(D)J recombination platform can facilitate the development of humanized mAbs with low immunogenicity and high binding affinities. This platform can directly transform numerous mAbs with therapeutic potential to humanized or even human therapeutic Abs for clinical use.

Immunogenicity and humanization of single‐domain antibodies

Prospects for the computational humanization of antibodies and nanobodies

Single-domain antibodies as therapeutics for solid tumor treatment

Antibody humanization—the Influence of the antibody framework on the CDR-H3 loop ensemble in solution

Application Progress of the Single Domain Antibody in Medicine

Antibody Humanization By A Single Cycle Of Cdr-Grafting

A single-domain antibody library based on a stability-engineered human VH3 scaffold

On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality

Single domain antibody: Development and application in biotechnology and biopharma

Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats

A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies

The process using a synthetic library that generates multiple diverse human single domain antibodies

Humanization Design of Antibody HAb18 Based on Variable Domain Resurfacing

Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Structure-based humanization of a therapeutic antibody for multiple myeloma

General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold*

Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Generative Humanization for Therapeutic Antibodies